How a derivative of CBG may help people with diseases like multiple sclerosis and Parkinson’s disease
According to a late 2012 report that was published in the Journal of Neuroimmune Pharmacology, a cannabigerol quinone appears to ameliorate neuroinflammation in a chronic model of MS.
More specifically, the researchers, Granja et al., looked at how a cannabigerol quinone, VCE-003, presented any possible anti-inflammatory properties.
When locating potential sites of activity, the researchers peered into the quinone’s behavior at CB1, CB2, and PPARy binding sites.
Their results showed several interesting findings, including that VCE-003:
- Protected neuronal cells from excitotoxicity
- Activated PPARγ transcriptional activity
- Inhibited the release of pro-inflammatory mediators in LPS-stimulated microglial cells
Granja et al. wanted to know how these properties manifested themselves in vivo. To understand it better, they used Theiler’s murine encephalomyelitis virus (TMEV) model of multiple sclerosis.
By looking at motor function performance and the neuroinflammatory response, the researchers found that VCE-003 “ameliorated the symptoms associated to TMEV infection, decreased microglia reactivity and modulated the expression of genes involved in MS pathophysiology.”
With studies like these, the authors of 2018 report published in the Journal of Neuroinflammation wanted to know if the CBG quinone VCE-003.2 shows any potential to help people suffering from Parkinson’s disease (PD).
By studying the results of experiments on mice with induced models of PD, the researchers indicated potential benefits. For example, by targeting PPARy receptors, this CBG quinone shows potential as a protective agent “against inflammation-driven neuronal damage.”